| By Ryan McGuire, Senior Research Analyst |
The megatrend of personalized medicine gained a significant boost of adrenaline recently as Vertex Pharmaceutical’s cystic fibrosis drug, Kalydeco (ivacaftor), earned FDA approval. As with much of personalized medicine’s recent news, behind the story beats the heart of a companion diagnostic. Continue reading “The Case for Companion Diagnostics” »
| By Shaylyn Pike, Senior Research Analyst |
Once upon a time, a brand team’s quest ended at marketing approval; revenues would take care of themselves. Fast forward 20 years, and the industry faces a much more challenging road to brand success. Receiving marketing authorization has become just another stage to complete. The more crucial step now is gaining and keeping the desired level of reimbursement.
A growing reliance on insurance companies and government payers to cover the cost of therapy has led to increased scrutiny of drug and device prices and benefits. With increases in patient populations and disease prevalence, payers no longer turn a blind eye to rising prices necessary to recoup product development costs. To successfully maintain their business model Continue reading “Communicating the Value of Innovation through Health Economics Analysis” »
| By Yanis Saradjian, Director of Consulting |
Our newly updated Fair-Market Value Benchmarking and Analysis service now provides medical, scientific and regulatory staff at life sciences companies with fair-market value benchmarks for thought leaders and influential physicians in more than 100 countries. The service is built upon a decade of detailed key opinion leader management research and the Research and Consulting teams’ expertise in FMV benchmarking and developing physician fee schedules. Continue reading “Fair-Market Value Benchmarking Service Provides KOL Compensation Data for More Than 100 Countries” »
| By Shaylyn Pike, Senior Research Analyst |
The emerging markets are not the United States, nor are they the European Union. It seems like a simple statement, but in Cutting Edge Information’s latest research on clinical development in the emerging markets, one finding rose to the top: the life sciences industry consistently tries to run emerging markets clinical trials the same way they run them in more developed markets. They just expect more favorable timelines and resource figures. Continue reading “Understanding Culture is Crucial for Successful Emerging Markets Clinical Trials” »
| By Jeremy Spivey, Senior Research Analyst |
The first few decisions of Germany’s new drug pricing body have arrived, and the results are mixed. Brilique (known as Brilinta in the United States) in December became the first product to complete the new product review process under Germany’s new drug evaluation law (AMNOG). It received a favorable opinion in one indication, allowing Brilinta manufacturer AstraZeneca to negotiate a price with the country’s public healthcare organization rather than be subjected to reference pricing. Continue reading “Brilinta and Trajenta are first drugs subjected to Germany’s new pricing law” »
| By Michelle Vitko, Research Analyst |
The Research team is right in the middle of our new study of patient adherence and compliance, and we’ve now interviewed executives from a variety of companies in the life sciences industry about their patient adherence groups’ reporting structures and organizational charts. Over half of all companies surveyed report having a dedicated team; the rest use staff on an ad-hoc basis. While no two companies have exactly the same structure due to different needs and resources available, several trends have emerged. Continue reading “Data Sneak Peek: Groups Involved in Patient Adherence Teams” »
Distinct salary bands are emerging for new hire and senior liaisons as the function matures
With health outcomes liaisons in high demand, life sciences companies must offer a competitive salary package and a career map to attract and retain effective HOLs, according to our recent research. The study detailed compensation figures for US- and EU-based HOLs at different levels of experience: no experience, two years of experience and five years of experience. “Health Outcomes Liaisons: Managing a Field-Based Team that Speaks the Payer’s Language” also shows the financial benefit of increased experience. While Continue reading “Health Outcomes Liaisons Teams Need to Meet Compensation and Professional Development Benchmarks to Grow” »
